PDB26 ESTIMATED RENAL AND CARDIOVASCULAR OUTCOMES AND COST OFFSETS IN PATIENTS WITH TYPE 2 DIABETES (T2D) AND DIABETIC NEPHROPATHY (DKD) TREATED WITH CANAGLIFLOZIN
Abstract
Authors
M. Willis M. Durkin C. Neslusan S. Traina A. Nilsson